Resolving the ductal carcinoma in situ treatment conundrum

Journal of the National Cancer Institute

Volumn 105, Issue 10, 2013, Pages 680-681

  Berg, Christine D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; EDITORIAL; HORMONAL THERAPY; INTRADUCTAL CARCINOMA; PARTIAL MASTECTOMY; PRIORITY JOURNAL;

EID: 84877969302     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt097     Document Type: Editorial

References (5)

1. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the Science Conference statement: diagnosis and management of ductal carcinoma in situ, September 22-24, 2009. J Natl Cancer Inst. 2010;102(3):161-169.
2. Silverstein MJ, Lagios MD. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr. 2010;2010(41):193-196.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-177.
4. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701-710.
5. Morrow M, Winograd JM, Freer PE, Eichhorn JH. Case 8-2013-a 48-year-old woman with carcinoma in situ of the breast. N Engl J Med. 2013;368(11): 1046-1053.